Ash 2021 – Bristol reveals its sons of Revlimid
Data in multiple myeloma and non-Hodgkin’s lymphoma make Bristol optimistic about follow-ons to Revlimid and Pomalyst.
Bayer beefs up discovery work with Vividion buyout
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Biopharma venture investors shrug off Covid-19
First-quarter venture investments barely register the pandemic - huge cash reserves should protect funding for biotech start-ups this year.
Smaller groups await Bristol-Myers Squelgene fallout
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?